Aprea Therapeutics financials
$0.7696+2.37%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $3.3K | $1.8K | $118.1K | $162.5K | $205.8K | $354.6K | $561.6K | $380.6K | $14.1K | $319.5K |
| Gross profit | $0.00 | $0.00 | $3.3K | $1.8K | $118.1K | $162.5K | $205.8K | $354.6K | $561.6K | $380.6K | $14.1K | $319.5K |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$4.0M | -$3.4M | -$2.6M | -$3.1M | -$3.4M | -$4.1M | -$3.2M | -$4.1M | -$3.8M | -$3.1M | -$3.7M | -$3.5M |
| Net income | -$3.6M | -$3.3M | -$2.5M | -$3.0M | -$3.2M | -$3.9M | -$2.9M | -$3.8M | -$3.5M | -$2.8M | -$3.4M | -$3.2M |
| Net margin | — | — | −73588.0% | −160844.7% | −2742.2% | −2420.6% | −1406.5% | −1067.0% | −617.9% | −738.4% | −24463.6% | −1003.1% |
| Diluted EPS | $-0.07 | $-0.22 | $-0.32 | $-0.47 | $-0.53 | $-0.66 | $-0.49 | $-0.64 | $-0.58 | $-0.67 | $-0.92 | $-0.86 |
| EBITDA | -$4.0M | -$3.4M | -$2.6M | -$3.1M | -$3.4M | -$4.1M | -$3.2M | -$4.1M | -$3.8M | -$3.1M | -$3.7M | -$3.5M |
| Operating cash flow | -$3.3M | -$2.8M | -$3.0M | -$3.2M | -$3.1M | -$3.6M | -$3.5M | -$2.5M | -$3.6M | -$3.9M | -$3.7M | -$2.2M |
| Free cash flow | -$3.3M | -$2.8M | -$3.0M | -$3.2M | -$3.1M | -$3.6M | -$3.5M | -$2.5M | -$3.6M | -$3.9M | -$3.7M | -$2.3M |
| Diluted shares | 53.5M | 14.7M | 7.7M | 6.4M | 6.1M | 6.0M | 6.0M | 5.9M | 5.9M | 4.2M | 3.7M | 3.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $41.2M | $46.5M | $14.6M | $13.7M | $16.5M | $19.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $42.3M | $47.6M | $15.9M | $14.3M | $17.3M | $20.2M |
| Total liabilities | $3.1M | $5.3M | $2.8M | $2.7M | $3.2M | $3.4M |
| Shareholders' equity | $38.5M | $41.6M | $12.4M | $10.9M | $13.4M | $15.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology